Insulin Pump Segment to Lead mHealth Market During 2021-2028

According to our latest study on "mHealth Market Forecast to 2028 - COVID-19 Impact and Analysis - by Service, Devices, and End User" the market is projected to reach US$ 410.39 billion by 2028 from US$ 70.83 billion in 2021; it is estimated to grow at a CAGR of 28.5% from 2021 to 2028. The report highlights the key factors and trends impacting the market and focuses on prominent players and their game-changing strategies. The increasing adoption of smartphones and other mobile platforms, and rapid spread of COVID-19 are driving the mHealth market progress. However, security and privacy issues hinder the market growth.

Based on device, the mHealth market is segmented into insulin pump, BP monitor, glucose monitor, personal pulse oximeter, and other devices. The insulin pump devices segment held a larger market share in 2021. However, the personal pulse oximeter segment is anticipated to register the highest CAGR during the forecast period.

Diabetes is a chronic, metabolic disorder that refers to the condition created by the body's inability to regulate glucose levels. The medical profession has postulated that patients could benefit from a system providing continuous glucose readings. The number of people with diabetes is increasing across the world, and ~90% of patients diagnosed with the condition have Type 2 diabetes mellitus; about one-fifth of people with Type 2 diabetes are on insulin treatment. The global burden of Type 2 diabetes has prompted efforts to develop mobile technologies for self-monitoring of blood glucose. More than 30 million Americans have some form of diabetes mellitus, which includes Type 1 diabetes, Type 2 diabetes, and gestational diabetes. Patients with diabetes have prolonged periods of high blood glucose, which results from insufficient levels of insulin or an inadequate cellular response to insulin. In the US, Type 2 (insulin-resistant) diabetes accounts for ~90-95% of all patients with diabetes, while Type 1 (insulin-insufficient) diabetes accounts for 5%. Management of diabetes varies depending on the type and severity. For Type 1 diabetes patients, insulin is a life-long treatment, with a wide spectrum of doses including multiple dose injections or insulin pumps (also known as continuous subcutaneous insulin infusion). A wide variety of home glucometers are available that are portable, inexpensive, reliable, and sensitive, and these machines use smaller volumes of blood than their conventional counterparts. Wearable insulin pumps and continuous glucose monitoring systems (CGMS) have given more freedom to many individuals with diabetes, along with providing scope for better treatments with real-time monitoring. Insulin deficiency can have serious side effects. By wearing CGMs and insulin pumps, patients are less likely to experience insulin deficiency. Moreover, when connected to a smartphone app, a CGMS or insulin pump gives continuous glucose updates. CGMS collect data so patients can identify trends and triggers.

Allscripts Healthcare LLC, Koninklijke Philips N.V., Medtronic, Boston Scientific Corp., athenaheath Inc., Honeywell Life Care Solutions, Cisco Systems Inc., Omron Corp., Masimo, and AgaMatrix Inc. are among the leading companies operating in the global mHealth market.

Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com